Regeneron Pharmaceuticals (NASDAQ:REGN) Shareholders Have Enjoyed A 32% Share Price Gain
While Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 15% in the last quarter. But that doesn't change the reality that over twelve months the stock has done really well. After all, the share price is up a market-beating 32% in that time.
Check out our latest analysis for Regeneron Pharmaceuticals
To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.
During the last year Regeneron Pharmaceuticals grew its earnings per share (EPS) by 48%. It's fair to say that the share price gain of 32% did not keep pace with the EPS growth. So it seems like the market has cooled on Regeneron Pharmaceuticals, despite the growth. Interesting.
The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers).
We know that Regeneron Pharmaceuticals has improved its bottom line over the last three years, but what does the future have in store? If you are thinking of buying or selling Regeneron Pharmaceuticals stock, you should check out this FREE detailed report on its balance sheet.
A Different Perspective
We're pleased to report that Regeneron Pharmaceuticals shareholders have received a total shareholder return of 32% over one year. Notably the five-year annualised TSR loss of 1.5% per year compares very unfavourably with the recent share price performance. We generally put more weight on the long term performance over the short term, but the recent improvement could hint at a (positive) inflection point within the business. It's always interesting to track share price performance over the longer term. But to understand Regeneron Pharmaceuticals better, we need to consider many other factors. Take risks, for example - Regeneron Pharmaceuticals has 1 warning sign we think you should be aware of.
But note: Regeneron Pharmaceuticals may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.
This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.
